Skip to main content
Article thumbnail
Location of Repository

Update on Intra-Arterial Chemotherapy for Retinoblastoma.

By Mario Zanaty, Guilherme Barros, Nohra MD Chalouhi, Robert M Starke, Philip Manasseh, Stavropoula I Tjoumakaris, Carol L Shields, David Hasan, Ketan Bulsara, Robert H. Rosenwasswer MD and MD Pascal Jabbour

Abstract

The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy (IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications, complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies

Topics: cancer chemotherapy, cancer control, catheterization, cryotherapy, drug cost, drug efficacy, drug safety, enucleation, health care cost, human, intraarterial drug administration, laser coagulation, quality of life, retinoblastoma, Review, transpupillary thermotherapy, treatment indication, Neurology, Surgery
Publisher: Jefferson Digital Commons
Year: 2014
OAI identifier: oai:jdc.jefferson.edu:neurosurgeryfp-1069

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.